Eli Lilly and Company
LLY
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The compaā¦ read more
Healthcare
Drug ManufacturersāGeneral
54 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$1,115.25
Price-0.69%
-$7.75
1Y
Price
Market Cap
$1.050t
Large
Price/Earnings 3y Avg5y Avg
35.4x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+40.3%
EBITDA Margin+30.9%
Net Profit Margin+33.8%
Free Cash Flow Margin+40.3%
EBITDA Margin+30.9%
Net Profit Margin+33.8%
Free Cash Flow MarginRevenue
$79.666b
+22.2%
1y CAGR+33.0%
3y CAGR+29.6%
5y CAGREarnings
$26.710b
+29.4%
1y CAGR+75.5%
3y CAGR+52.6%
5y CAGREPS
$29.80
+29.9%
1y CAGR+75.9%
3y CAGR+54.0%
5y CAGRBook Value
$33.879b
$142.283b
Assets$108.404b
Liabilities$54.908b
DebtDebt to Assets
38.6%
1.6x
Debt to EBITDAFree Cash Flow
$20.054b
+123.5%
1y CAGR+767.4%
3y CAGR+533.4%
5y CAGRNo items found.
Press Releases
Statements and updates from the company